Seizert Capital Partners’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$35.4M Sell
120,839
-5,093
-4% -$1.67M 1.63% 29
2025
Q4
$44.1M Sell
125,932
-1,894
-1% -$640K 1.86% 24
2025
Q3
$41.3M Sell
127,826
-6,027
-5% -$1.87M 1.79% 28
2025
Q2
$52.1M Buy
133,853
+77
+0.1% +$31K 2.29% 14
2025
Q1
$58.2M Buy
133,776
+3,514
+3% +$1.41M 2.67% 7
2024
Q4
$48.1M Buy
130,262
+26,033
+25% +$10.9M 2.17% 17
2024
Q3
$54.2M Buy
104,229
+21,708
+26% +$11.6M 2.45% 9
2024
Q2
$44.7M Sell
82,521
-4,627
-5% -$2.45M 2.22% 14
2024
Q1
$45.2M Buy
87,148
+1,221
+1% +$607K 2.08% 16
2023
Q4
$40.5M Sell
85,927
-148
-0.2% -$68.4K 2.05% 16
2023
Q3
$37.5M Buy
86,075
+1,394
+2% +$632K 1.99% 17
2023
Q2
$37.6M Sell
84,681
-170
-0.2% -$78.4K 2.02% 18
2023
Q1
$39M Sell
84,851
-3,037
-3% -$1.45M 2.15% 14
2022
Q4
$45.1M Sell
87,888
-132
-0.1% -$67K 2.39% 10
2022
Q3
$40M Buy
88,020
+380
+0.4% +$182K 2.25% 11
2022
Q2
$42.3M Sell
87,640
-12,631
-13% -$6.25M 2.24% 9
2022
Q1
$49.3M Sell
100,271
-2,173
-2% -$993K 2.26% 11
2021
Q4
$47.5M Sell
102,444
-2,921
-3% -$1.23M 2.12% 15
2021
Q3
$39.3M Buy
105,365
+3,239
+3% +$1.23M 1.8% 20
2021
Q2
$39M Buy
102,126
+2,863
+3% +$1.09M 1.86% 21
2021
Q1
$35.6M Buy
99,263
+6,415
+7% +$2.06M 1.86% 17
2020
Q4
$29.8M Sell
92,848
-3,869
-4% -$1.19M 1.74% 22
2020
Q3
$26M Buy
96,717
+726
+0.8% +$195K 1.71% 29
2020
Q2
$25.2M Buy
95,991
+15,083
+19% +$4.02M 1.71% 24
2020
Q1
$18.4M Sell
80,908
-9,372
-10% -$2.55M 1.35% 34
2019
Q4
$27.3M Sell
90,280
-3,877
-4% -$1.07M 1.36% 29
2019
Q3
$22.6M Sell
94,157
-5,115
-5% -$1.4M 1.14% 34
2019
Q2
$28M Buy
99,272
+12,390
+14% +$3.38M 1.38% 29
2019
Q1
$24.9M Sell
86,882
-198
-0.2% -$57.3K 1.12% 39
2018
Q4
$22.9M Buy
87,080
+2,853
+3% +$785K 1.03% 45
2018
Q3
$23.1M Sell
84,227
-8,181
-9% -$2.12M 0.85% 50
2018
Q2
$20.3M Hold
92,408
0.74% 51
2018
Q1
$20.3M Sell
92,408
-8,855
-9% -$2.08M 0.74% 51
2017
Q4
$22.8M Sell
101,263
-20,354
-17% -$4.34M 0.82% 49
2017
Q3
$23.1M Buy
121,617
+249
+0.2% +$47.4K 0.85% 47
2017
Q2
$22.8M Sell
121,368
-1,257
-1% -$226K 0.83% 47
2017
Q1
$20.3M Sell
122,625
-56,424
-32% -$8.98M 0.72% 52
2016
Q4
$25.7M Sell
179,049
-29,151
-14% -$3.9M 0.91% 46
2016
Q3
$26.1M Buy
208,200
+84,435
+68% +$10.9M 0.97% 42
2016
Q2
$16.3M Sell
123,765
-2,248
-2% -$308K 0.62% 56
2016
Q1
$17.5M Sell
126,013
-10,038
-7% -$1.34M 0.6% 56
2015
Q4
$19M Buy
136,051
+14,692
+12% +$2.02M 0.59% 56
2015
Q3
$17M Buy
121,359
+3,460
+3% +$520K 0.51% 60
2015
Q2
$19.4M Sell
117,899
-49,151
-29% -$7.85M 0.49% 64
2015
Q1
$25.8M Sell
167,050
-151,823
-48% -$21.6M 0.65% 58
2014
Q4
$40.1M Sell
318,873
-12,119
-4% -$1.5M 0.85% 54
2014
Q3
$39.6M Sell
330,992
-5,553
-2% -$637K 0.79% 55
2014
Q2
$36.2M Buy
336,545
+8,615
+3% +$888K 0.72% 55
2014
Q1
$32.6M Sell
327,930
-1,485
-0.5% -$134K 0.76% 57
2013
Q4
$30.4M Buy
329,415
+32,623
+11% +$2.9M 0.72% 57
2013
Q3
$24.8M Buy
+296,792
New +$25.4M 0.68% 58

Other funds holding ELV

Seizert Capital Partners's ELV Position: Q1 2026 in Review

Seizert Capital Partners reduced its Elevance Health (ELV) stake by 4% in Q1 2026, selling an estimated $1.67M and leaving 120,839 shares worth $35.4M. The position accounts for 1.63% of the portfolio, ranked #29.

Seizert Capital Partners first reported a position in ELV in Q3 2013 and has held it in 51 quarters since. The position peaked at $58.2M in Q1 2025. 1,464 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • Seizert Capital Partners held 120,839 shares of Elevance Health worth $35.4M as of Q1 2026.
  • Seizert Capital Partners sold 5,093 Elevance Health shares in Q1 2026, an estimated $1.67M.
  • Elevance Health made up 1.63% of Seizert Capital Partners's portfolio in Q1 2026, its #29 holding.
  • Seizert Capital Partners first reported a position in Elevance Health in Q3 2013 and has held it in 51 quarters since.
  • Seizert Capital Partners's Elevance Health position peaked at $58.2M in Q1 2025.
  • 1,464 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on Seizert Capital Partners's 13F filing for Q1 2026, filed 7 May 2026.